NASDAQ
4.81USD
-0.15 (-3.02%)
We have scored 27 news catalysts on Unicycive Therapeutics, Inc. (UNCY) over the past 12 months. The biggest single-day move next to one of them came Jun 30, 2026, when UNCY closed −39.1%: “Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors”. Coverage across the window leans negative (average ticker sentiment −0.77). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
128.4M
P/E
—
EPS
—
Beta
1.78
52W range
3.71-8.74
Day range
4.73–4.96
Open
4.94
Prev close
4.96
Volume
693.7K
Avg volume
1.3M
Dividend
0.00
IPO
2021-07-12
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Unicycive Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for UNCY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
